Real world study of afatinib in first-line or re-challenge setting for patients with EGFR mutant non-small cell lung cancer.

Hisashi Tanaka,Kageaki Taima,Masamichi Itoga,Yoshiko Ishioka,Keisuke Baba,Toshihiro Shiratori,Yoshihito Tanaka,Hideyuki Nakagawa,Junichiro Tsuchiya,Yukihiro Hasegawa,Hiroaki Sakamoto,Hideo Yasugahira,Koichi Okudera,Shingo Takanashi,Sadatomo Tasaka

Real world study of afatinib in first-line or re-challenge setting for patients with EGFR mutant non-small cell lung cancer.

2018

Hisashi Tanaka
Kageaki Taima
Masamichi Itoga
Yoshiko Ishioka
Keisuke Baba
Toshihiro Shiratori
Yoshihito Tanaka
Hideyuki Nakagawa
Junichiro Tsuchiya
Yukihiro Hasegawa
Hiroaki Sakamoto
Hideo Yasugahira
Koichi Okudera
Shingo Takanashi
Sadatomo Tasaka

e21173Background: Afatinib is the second generation epidermal growth factor receptor (EGFR) - tyrosine kinase inhibitor (TKI) for mutant non-small cell lung cancer (NSCLC), and approved in Japan in...

Keywords:

Cell
Afatinib
Cancer research
Pathology
Mutant
Lung cancer
Medicine
Epidermal growth factor receptor
first line
non small cell
Tyrosine-kinase inhibitor
re challenge

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations